Clinical Trials › NCT05269004

Active, Not RecruitingPhase 3

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

Sponsored by Hoffmann-La Roche

Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov
1300
Target enrollment
26
U.S. states
May 2022
Start date
Dec 2027
Expected completion
Interventions / Treatments
Ocrelizumab
Conditions studied
Multiple Sclerosis
Where this trial is running (50 sites)
Florida5 sites
Maitland · Miami · Orlando · +2 more
California4 sites
Laguna Hills · Palo Alto · San Francisco · +1 more
North Carolina4 sites
Charlotte · Charlotte · Charlotte · +1 more
Texas4 sites
Houston · Houston · Lubbock · +1 more
Michigan3 sites
Detroit · Detroit · Farmington Hills
Arizona2 sites
Phoenix · Phoenix
Colorado2 sites
Aurora · Fort Collins
Illinois2 sites
Chicago · Northbrook
Minnesota2 sites
Golden Valley · Minneapolis
New Jersey2 sites
Newark · Teaneck
New York2 sites
Patchogue · Stony Brook
Ohio2 sites
Cincinnati · Westerville
Tennessee2 sites
Cordova · Knoxville
Washington2 sites
Seattle · Tacoma
Georgia1 site
Atlanta
Indiana1 site
Indianapolis
Kansas1 site
Kansas City
Massachusetts1 site
Boston
Missouri1 site
St Louis
Nebraska1 site
Omaha
New Mexico1 site
Albuquerque
Oklahoma1 site
Oklahoma City
Oregon1 site
Portland
Pennsylvania1 site
Abington
Rhode Island1 site
Providence
Vermont1 site
Burlington
Participating MS centers on MS Buddy (31)
MS centers in Florida

Compare treatment centers near a trial site — patient experience, providers, and care ratings.

View Florida centers
More Phase 3 trials
Browse all Phase 3 MS trials

Check out the MS Buddy App

Track symptoms, monitor wellness, and stay on top of your MS care. It's free, no ads. How? It's made and supported by MS patients who get their ideas from other MS patients.

Download on the App StoreGet it on Google Play